Atrial fibrillation in hypertrophic cardiomyopathy – A contemporary mini-review

MacIntyre, 2016, Management of atrial fibrillation in hypertrophic cardiomyopathy, Circulation, 133, 1901, 10.1161/CIRCULATIONAHA.115.015085 Maron, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults, Circulation, 92, 785, 10.1161/01.CIR.92.4.785 Olivotto, 2015, Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations, Cardiovasc Res, 105, 409, 10.1093/cvr/cvv024 Elliott, 2014, ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 Olivotto, 2001, Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy, Circulation, 104, 2517, 10.1161/hc4601.097997 Maron Barry, 2002, Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 39, 301, 10.1016/S0735-1097(01)01727-2 Tian, 2013, Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy, Cardiology, 126, 258, 10.1159/000354953 Siontis Konstantinos, 2014, Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population, J Am Heart Assoc, 3 Guttmann, 2014, Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review, Heart, 100, 465, 10.1136/heartjnl-2013-304276 Guttmann Oliver, 2015, Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA), Eur J Heart Fail, 17, 837, 10.1002/ejhf.316 Ahmad, 2015, Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography, Am Heart J, 169, 684, 10.1016/j.ahj.2015.02.006 Rowin, 2017, Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy, Circulation, 136, 2420, 10.1161/CIRCULATIONAHA.117.029267 Rowin, 2017, Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy, Am J Cardiol, 119, 1862, 10.1016/j.amjcard.2017.02.040 Kirchhof, 2016, 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Europace, 18, 1609, 10.1093/europace/euw295 Lee, 2017, Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy, Heart, 103, 1496, 10.1136/heartjnl-2016-310720 January, 2019, 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation, Circulation, 140, e125, 10.1161/CIR.0000000000000665 Maron, 2012, Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives, J Am Coll Cardiol, 60, 705, 10.1016/j.jacc.2012.02.068 Richard, 2003, EUROGENE Heart Failure Project. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54 Hartmannova, 2013, Isolated X-linked hypertrophic cardiomyopathy caused by a novel mutation of the four-and-a-half LIM domain 1 gene, Circ Cardiovasc Genet, 6, 543, 10.1161/CIRCGENETICS.113.000245 Prinz, 2012, In patients with hypertrophic cardiomyopathy myocardial fibrosis is associated with both left ventricular and left atrial dysfunction, Acta Cardiol, 67, 187, 10.1080/AC.67.2.2154209 Papavassiliu, 2009, Borggrefe M. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation, J Cardiovasc Magn Reson, 11, 34, 10.1186/1532-429X-11-34 Efremidis, 2021, Atrial substrate characterization in patients with atrial fibrillation and hypertrophic cardiomyopathy: Evidence for an extensive fibrotic disease, J Electrocardiol. Nov-Dec, 69, 87, 10.1016/j.jelectrocard.2021.06.001 Debonnaire, 2017, Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation, Circ Arrhythm Electrophysiol, 10, e004052, 10.1161/CIRCEP.116.004052 Losi, 2004, Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy, Am J Cardiol, 94, 895, 10.1016/j.amjcard.2004.06.024 Paraskevaidis, 2009, Two-dimensional strain analysis in patients with hypertrophic cardiomyopathy and normal systolic function: a 12-month follow-up study, Am Heart J, 158, 444, 10.1016/j.ahj.2009.06.013 Tani, 2004, Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 17, 644, 10.1016/j.echo.2004.02.010 Nakao, 2021, Relation of Left Atrial Flow, Volume, and Strain to Paroxysmal Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy, Am J Cardiol, 17, 1140 Sivalokanathan, 2019, Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging, JACC Clin Electrophysiol, 5, 364, 10.1016/j.jacep.2018.10.016 Tayal, 2021, Hemodynamic determinants of left atrial strain in patients with hypertrophic cardiomyopathy: A combined echocardiography and CMR study, PLoS One, 16, 10.1371/journal.pone.0245934 Zegkos, 2021, The predictive value of left ventricular and left atrial mechanics for atrial fibrillation and heart failure in hypertrophic cardiomyopathy: a prospective cohort study, Int J Cardiovasc Imag, 37, 2679, 10.1007/s10554-021-02232-0 Raman, 2021, Incremental value of left atrial booster and reservoir strain in predicting atrial fibrillation in patients with hypertrophic cardiomyopathy: A cardiovascular magnetic resonance study, J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson., 23, 109 G Pontecorboli, D Lazzeroni, N Fierro, et al.. Mitral annular plane systolic excursion on cardiac magnetic resonance imaging as a predictor of atrial fibrillation in hypertrophic cardiomyopathy. European Heart Journal - Cardiovascular Imaging, Volume 20, Issue Supplement_2, June 2019, jez116.023, https://doi.org/10.1093/ehjci/jez116.023. A Castelo, S Rosa, A Fiarresga et al.. Predictors of atrial fibrillation occurrence in patients with hypertrophic cardiomyopathy. Eur Heart J, Volume 41, Issue Supplement_2, November 2020, ehaa946.2083, https://doi.org/10.1093/ehjci/ehaa946.2083. Guttmann, 2017, Hypertrophic Cardiomyopathy Outcomes Investigators. Predictors of atrial fibrillation in hypertrophic cardiomyopathy, Heart, 103, 672, 10.1136/heartjnl-2016-309672 Zegkos, 2017, Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality, Hellenic J Cardiol, 58, 331, 10.1016/j.hjc.2017.01.027 Tjahjadi, 2021, Assessment of left atrial electro-mechanical delay to predict atrial fibrillation in hypertrophic cardiomyopathy, Eur Heart J Cardiovasc Imaging, 22, 589, 10.1093/ehjci/jeaa174 Carrick, 2021, Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation, The HCM-AF Score Circ Arrhythm Electrophysiol, 14, e009796, 10.1161/CIRCEP.120.009796 Lee, 2018, SHaRe Investigators. Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.118.005191 Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 Ommen, 2020, 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation, 142 Ahmad, 2017, Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis, Cardiovasc Diagn Ther, 7, 36, 10.21037/cdt.2016.11.23 Liao, 2021, Atrial fibrillation and the risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy - A nationwide cohort study, EClinicalMedicine, 34, 10.1016/j.eclinm.2021.100802 Fauchier, 2022, Lip. Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation, Stroke, 53, 497, 10.1161/STROKEAHA.121.034213 Doi, 2001, Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation, J Cardiol, 37, 133 Rowin, 2017, Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy, Circulation, 136, 2420, 10.1161/CIRCULATIONAHA.117.029267 Spirito, 2017, Atrial Fibrillation in Hypertrophic Cardiomyopathy. New Light on an Old Problem, Circulation, 136, 2437, 10.1161/CIRCULATIONAHA.117.031743 Nazer, 2020, Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study, Heart Rhythm, 17, 1107, 10.1016/j.hrthm.2020.02.008 Rujirachun, 2020, Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis, Acta Cardiol, 75, 724, 10.1080/00015385.2019.1668113 Lee, 2019, Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation, Stroke, 50, 2582, 10.1161/STROKEAHA.119.026048 Nasser, 2021, Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: A review, Heart Rhythm, 18, 297, 10.1016/j.hrthm.2020.09.018 Lin, 2022, Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation, Heart Ves, 10.1007/s00380-022-02021-2 Huang, 2018, Chia-Ti Tsai, Juey-Jen Hwang, Pau-Chung Chen, Jiunn-Lee Lin. Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy, Heart, 104, 1276, 10.1136/heartjnl-2017-312573 Miller, 2019, Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy, Am J Cardiol, 123, 1859, 10.1016/j.amjcard.2019.02.051 Guy, 2020, Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy, J Am Heart Assoc, 9 Leon, 2021, Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Treatment Strategy, Characteristics of Consecutive Atrial Tachycardia and Long-Term Outcome, J Am Heart Assoc, 10 Calkins, 2017, HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, Heart Rhythm, 14, e445, 10.1016/j.hrthm.2017.07.009 Santangeli, 2013, Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence Circ, Arrhythm Electrophysiol, 6, 1089, 10.1161/CIRCEP.113.000339 Dinshaw, 2020, Ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: treatment strategy, characteristics of consecutive tachycardia and long-term outcome, J Am Heart Assoc, 9 Wen, 2019, Depolarization and repolarization parameters on ECG predict recurrence after atrial fibrillation ablation in patients with hypertrophic cardiomyopathy, J Cardiovasc Electrophysiol, 30, 2405, 10.1111/jce.14137 Lapenna, 2017, Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy, Eur J Cardio Thorac Surg, 51, 1112, 10.1093/ejcts/ezx017 Hodges, 2020, Surgical ablation of atrial fibrillation in hypertrophic obstructive cardiomyopathy: Outcomes of a tailored surgical approach, J Card Surg, 35, 2957, 10.1111/jocs.14946 Meng, 2021, Front. Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy, Cardiovasc Med